EDP-305 Dose 1 + EDP-305 Dose 2 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Steatohepatitis
Conditions
Non-Alcoholic Steatohepatitis
Trial Timeline
Apr 25, 2018 → Jul 10, 2019
NCT ID
NCT03421431About EDP-305 Dose 1 + EDP-305 Dose 2 + Placebo
EDP-305 Dose 1 + EDP-305 Dose 2 + Placebo is a phase 2 stage product being developed by Enanta Pharmaceuticals for Non-Alcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03421431. Target conditions include Non-Alcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03421431 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Alcoholic Steatohepatitis